Paper Review Records
All Paper Review Records
16 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
The Scandinavian Neurotrauma Committee 2026 guidelines for initial management of minimal, mild and moderate head injuries in adults: a systematic review, meta-analysis and modified Delphi consensus study
Li Jin Yang; Johan Undén; Alexander Fletcher-Sandersjöö; Jussi P. Posti; Karoline Skogen; Mads Aarhus; Ramona Åstrand; Eric P. ThelinShow moreShow less
Department of Emergency Medicine, Stockholm South General Hospital, Stockholm, Sweden; Department of Clinical Science and Education Södersjukhuset, Karolinska Institutet, Stockholm, Sweden; Department of Operation and Intensive Care, Halland Hospital Halmstad, Region Halland, Halmstad, Sweden; Department of Clinical Sciences, Lund University, Lund, Sweden; Department of Neurosurgery, Karolinska University Hospital, Stockholm, Sweden; Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden; Neurocenter, Department of Neurosurgery and Turku Brain Injury Center, Turku University Hospital, Turku, Finland; Department of Clinical Neurosciences, Neurosurgery, University of Turku, Turku, Finland; Department of Radiology and Nuclear Medicine, Oslo University Hospitals, Oslo, Norway; Department of Neurosurgery, Oslo University Hospital, Oslo, Norway; Faculty of Medicine, University of Oslo, Oslo, Norway; Department of Neurosurgery, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark; Medical Unit Neurology, Karolinska University Hospital, Stockholm, SwedenShow moreShow less
Prevalence and mortality of chronic extracellular matrix dysregulated diseases: a nationwide register-based study
Rosa C. Christiansen; Cecilie L. Bager; Andrea Heinz; Anne C. Bay-Jensen; Diana J. Leeming; Dinesh Khanna; Federica Genovese; Florian Rieder; Georg Schett; Joachim H. Mortensen; Kim Henriksen; Nicholas Willumsen; Philip G. Conaghan; Raghu Kalluri; Scott L. Friedman; Signe Holm Nielsen; Signe Larsen; Stephane Heymans; Toby M. Maher; Søren Brunak; Morten A. KarsdalShow moreShow less
Nordic Bioscience, Herlev, Denmark; Department of Public Health, Section for Health Data Science and AI, University of Copenhagen, Copenhagen, Denmark; Department of Pharmacy, LEO Foundation Center for Cutaneous Drug Delivery, University of Copenhagen, Copenhagen, Denmark; Division of Rheumatology, University of Michigan, Ann Arbor, MI, USA; Department of Gastroenterology, Hepatology and Nutrition, Digestive Diseases Institute, Cleveland Clinic, Cleveland, OH, USA; Department of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH, USA; Program for Global Translational Inflammatory Bowel Disease, Cleveland Clinic, Cleveland, OH, USA; Friedrich-Alexander-Universität Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054, Erlangen, Germany; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK; National Institute for Health and Care Research Leeds Biomedical Research Centre, Leeds, UK; Department of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Bioengineering, Rice University, Houston, TX, USA; Department of Electrical and Computer Engineering, Rice University, Houston, TX, USA; Department of Pathology, University of Texas Medical Branch, Galveston, TX, USA; Institute for Liver Research, Icahn School of Medicine at Mount Sinai, New York, USA; Department of Cardiology, Cardiovascular Research Institute Maastricht, University of Maastricht & Maastricht University Medical Centre, Maastricht, Netherlands; Department of Cardiovascular Sciences, Centre for Vascular and Molecular Biology, KU Leuven, Leuven, Belgium; Hastings Centre for Pulmonary Research and Division of Pulmonary, Critical Care and Sleep Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA; National Heart and Lung Institute, Imperial College London, London, UKShow moreShow less
Sex- and age-specific trends in prescription medication use, 2005–2025: a nationwide repeated cross-sectional study
Noémie Roland; Martin Thomsen Ernst; Jesper James Linde; Lotte Rasmussen; Anton PottegårdShow moreShow less
Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health, University of Southern Denmark, Odense, Denmark; Department of Cardiology, The Heart Center, Copenhagen University Hospital Rigshospitalet, Copenhagen, DenmarkShow moreShow less
Income-related differences in survival across disease categories in Sweden: a retrospective population-based register study
Vincent Mougin; Authia Gray; Mohsen Naghavi; Peter Allebeck; Jonas Minet Kinge; Eve E. Wool; Nicole Davis Weaver; Christopher J.L. Murray; Emilie E. AgardhShow moreShow less
Department of Global Public Health, Karolinska Institutet, Stockholm, Sweden; Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA; Department of Health Management and Health Economics, University of Oslo, Oslo, Norway; Norwegian Institute of Public Health, Oslo, NorwayShow moreShow less
Melanoma incidence in Norway, 1980–2024: a cohort study
Saha Samimi; Trude E. Robsahm; Reza GhiasvandShow moreShow less
Oslo Centre for Biostatistics and Epidemiology, Oslo University Hospital, Oslo, Norway; Faculty of Medicine, Institute for Medical Information Processing, Biometry and Epidemiology (IBE), LMU, Munich, Germany; Department of Research, Cancer Registry of Norway, Norwegian Institute of Public Health, Oslo, NorwayShow moreShow less
Clinical trials on medicinal products in the EU/EEA, 2013–2025: a cross-sectional analysis of CTIS and EudraCT data
Tiago Machado; Giacomo Capone; IJsbrand den Rooijen; Felix Bindt; Marta Marcelino; Jacobus van Wyk; Ana Zanoletty Perez; Laura Pioppo; Rui Santos Ivo; Peter ArlettShow moreShow less
INFARMED – Autoridade Nacional do Medicamento e Produtos de Saúde, I.P., Lisbon, 1749-004, Portugal; Laboratório de Farmacologia Clínica e Terapêutica, Faculdade de Medicina, Universidade de Lisboa, Lisbon, 1649-028, Portugal; European Medicines Agency, Amsterdam, 1083 HS, the Netherlands; Departamento de Farmácia, Farmacologia e Tecnologias em Saúde, Faculdade de Farmácia, Universidade de Lisboa, Lisbon, 1649-003, Portugal; Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London, WC1E 7HT, United KingdomShow moreShow less
FAQ
How long does Lancet Regional Health-Europe take to review a manuscript?
As of 2026-11-19, CrushSCI has 16 complete review records for Lancet Regional Health-Europe. The fastest paper went from submission to acceptance in 65 days (Effectiveness of a nature-based social prescribing intervention on loneliness and health-related quality of life among vulnerable urban adults (RECETAS-BCN): an observer-blinded randomised controlled trial, received 2026-05-27, accepted 2026-07-31); the slowest took 183 days. The average is 131.9 days and the median is 135.5 days.
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
